In summary, the loss of heterozygosity of HLA and the mutation of B2M dampen the processing and presentation of antigens, resulting in the inability of CD8+ T cells to recognize tumor antigens and specifically kill tumor cells, which represents an important mechanism of primary or acquired resistance to ICB therapy. This evidence concerns the gene B2M and neoplasm.